Ex Vivo Assay Using Whole Bone Marrow Environment to Investigate the Efficacy of Daratumumab in Multiple Myeloma
Vivia Biotech recently presented at the EHA Congress its novel ex vivo assay featuring daratumumab (DARA), a monoclonal antibody for treating Multiple Myeloma (MM).
Our approach uses patients’ bone marrow samples to evaluate this antibody’s efficacy by mimicking tumor microenvironment conditions.
Vivia ex vivo assay stratifies patients based on their response to DARA, detecting all mechanisms of action in killing plasma cells, including:
- Complement-dependent cytotoxicity (CDC),
- Antibody-dependent cellular cytotoxicity (ADCC) involving NK cells,
- Antibody-dependent cellular phagocytosis (ADCP) via macrophages, and
- Direct induction of cell death pathways
Vivia’s ex vivo assays can help to improve your monoclonal antibodies therapy development.
Vivia native environment ex vivo assays allow:
- Mimicking the in vivo tumor microenvironment
- Stratify patients based on their drug response
- Gain comprehensive insight into the mechanisms of monoclonal antibodies
- Simultaneously capture activities mediated by CDC, ADCC, ADCP, or direct apoptosis
- Detect target receptor expression and correlate it with monoclonal antibodies activity
- Compare monoclonal antibodies with established standard of care compounds
Don’t miss the opportunity to learn more about our ex vivo assays and the potential impact of your monoclonal antibodies in transforming patients’ treatment.